Latest Market Entry News

Memphasys secures exclusive Felix™ commercialisation agreement in Poland, marking its third European market entry with a two-year contract valued at approximately A$350,000.

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

1414 Degrees secured $8.45 million funding and inked major agreements to commercialise its SiNTL battery technology across AI data centres, drones, satellites and defence sectors.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.

Streamplay Studio Limited has reported its fifth straight quarter of positive operating cash flow, driven by strong customer receipts and strategic publishing deals. The company is advancing multiple game releases and expanding its cloud gaming footprint across new regions.

Sprintex boosted its commercial footprint in the June quarter with a 65% order book increase from Mest Water, a paid trial at Taiwan's TSMC, and Dutch regulatory clearance lifting key uncertainties.

Cleo Diagnostics has entered the critical Analytical Validation phase for its ovarian cancer blood test, progressing toward an FDA 510(k) submission targeted for the first half of 2027. The company also secured a U.S. reimbursement pathway to support early market entry post-clearance, backed by a cash balance of A$6.2 million.

De.mem Limited posted its second highest quarterly cash receipts of approximately $9.6 million for June 2026, marking 29 consecutive quarters of growth and positive operating cash flow of $424k. The company’s strong half-year performance is underpinned by recurring revenues, a robust Western Australian business, and record results from its German subsidiary.

Nodestream has advanced its defence strategy with key leadership hires, a $6.5 million capital raise, and fresh product launches, while expanding its footprint in the US and European markets.

DXN Limited has landed a $1.2 million contract for a key Pacific submarine cable project while advancing its maiden AI HPC modular data centre deal and expanding manufacturing in Southeast Asia.

LTR Pharma’s SPONTAN shows rapid absorption in Phase II interim data while securing key US commercial deals for ROXUS, setting the stage for a US market entry later this year.